The most advanced multiomic tissue test
that delivers maximum insights from minimal tissue.1,2
99% of samples successfully
reported out a result‡
NEW Clear, actionable multiomic insights¶ powered by InfinityAI
Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Multiomic insights from DNA,
RNA, and epigenomics1*
Lowest industry-wide
sample requirements1†
Home Screening MRD + Monitoring Treatment Selection
NGS, next-generation sequencing.
†92% less surface area, 2mm2 for Guardant360 Tissue vs. 25mm2 industry standard. When compared to the required sample input and QNS rates of other tissue testing companies. Comparisons are based on publicly available analytical specification information as of November 2025.
‡DNA only, when sample requirements are met. As of April 2026.
§With tissue input of ≥2mm2 surface area and ≥5% tumor cellularity. Referring to DNA performance only; RNA performance may vary.